The World Health Organization (WHO) has issued its recommendations for influenza vaccine development, targeting the 2026–2027 flu season. This proactive step comes as the current season continues, with significant illness and mortality already reported globally. The WHO’s announcement signals a shift towards preparing for both expected and potential pandemic strains.
Key Recommended Strains
Vaccine manufacturers have been advised to prioritize strains including:
- Influenza A (H1N1), commonly known as swine flu.
- Influenza A (H3N2), another prevalent A subtype.
- Influenza B (Victoria lineage), a common B-strain variant.
Beyond these standard recommendations, the WHO is urging preparation of candidate vaccine viruses for H9N2 bird flu, recognizing the potential for zoonotic spillover and future pandemics. This emphasis on bird flu reflects growing concerns about animal-to-human transmission of influenza viruses.
Current Season’s Impact
The 2024–2025 flu season has already been severe, with the U.S. Centers for Disease Control and Prevention (CDC) reporting over 25 million illnesses and 20,000 deaths, including 79 children. High hospitalization rates are partly driven by the emergence of a new variant, subclade K, which demonstrates some ability to evade existing vaccine protection. This highlights the constant evolutionary pressure on influenza viruses and the need for continuous vaccine updates.
Zoonotic Flu Risks and Future Vaccines
The WHO also reports at least 25 human cases of influenza acquired from animals since last September, primarily through exposure to infected livestock or contaminated environments. While human-to-human transmission of these zoonotic strains remains limited, the organization stresses preparedness.
The landscape of flu vaccination may soon change, as the U.S. Food and Drug Administration (FDA) is now reviewing an mRNA flu vaccine developed by Moderna. mRNA vaccines, proven effective against COVID-19, offer faster production and adaptation to emerging variants—a crucial advantage in responding to strains like subclade K that appear after seasonal shots are already distributed.
The WHO’s preemptive vaccine guidance and the evaluation of mRNA technology demonstrate a commitment to both immediate public health needs and long-term pandemic preparedness.
The constant evolution of influenza viruses underscores the necessity for ongoing research, surveillance, and flexible vaccine production strategies to mitigate the global threat of seasonal and pandemic outbreaks.
